Cullinan Therapeutics (NASDAQ:CGEM) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Cullinan Therapeutics (CGEM) operate in?

Cullinan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cullinan Therapeutics Stock (NASDAQ: CGEM) stock price, news, charts, stock research, profile.

Open	$11.61
Close	$11.87
Volume / Avg.	714.79K / 544.27K
Day Range	$11.34 - $11.97
52 Wk Range	8.49 - 30.19
Market Cap	$691.16M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	33
Short Interest	18.23%
Days to Cover	16.92

Recent News

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Avi Kapoor

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent dosing benefits.

Vandana Singh

Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst

Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims to advance Merck's pipeline for treating B-cell malignancies and autoimmune diseases. The deal, valued at up to $1.3 billion, is expected to close in Q3 2024.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug

Sep

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$11.61
Close	$11.87
Volume / Avg.	714.79K / 544.27K
Day Range	$11.34 - $11.97
52 Wk Range	8.49 - 30.19
Market Cap	$691.16M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	33
Short Interest	18.23%
Days to Cover	16.92

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cullinan Therapeutics (CGEM) stock?

You can purchase shares of Cullinan Therapeutics (NASDAQ:CGEM) through any online brokerage.

View our list of the best stock brokerages

Who are Cullinan Therapeutics (CGEM) competitors?

Other companies in Cullinan Therapeutics’s space includes: Tectonic Therapeutic (NASDAQ:TECX), Immunome (NASDAQ:IMNM), Humacyte (NASDAQ:HUMA), Altimmune (NASDAQ:ALT) and Pharming (NASDAQ:PHAR).

What is the forecast, or price target, for Cullinan Therapeutics (CGEM) stock?

Cullinan Therapeutics has a consensus price target of $29.25.

What is the current price for Cullinan Therapeutics (CGEM)?

The stock price for Cullinan Therapeutics (NASDAQ: CGEM) is $11.87 last updated December 23, 2024 at 4:40 PM EST.

Does Cullinan Therapeutics (CGEM) pay a dividend?

There are no upcoming dividends for Cullinan Therapeutics.

When is Cullinan Therapeutics (NASDAQ:CGEM) reporting earnings?

Cullinan Therapeutics’s Q4 earnings are confirmed for Thursday, March 13, 2025.

Is Cullinan Therapeutics (CGEM) going to split?

There is no upcoming split for Cullinan Therapeutics.

What sector and industry does Cullinan Therapeutics (CGEM) operate in?

Cullinan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Cullinan Therapeutics

Cullinan Therapeutics (CGEM) Forecast